

23 JANUARY 2015 – 5 :45 PM CET

## CARDIO3 BIOSCIENCES ANNOUNCES ITS 2015 FINANCIAL CALENDAR

**Mont-Saint-Guibert, Belgium** - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery and development of regenerative, protective and reconstructive therapies publishes its financial calendar for 2015.

Financial publications will be released after market close. This schedule is indicative and subject to change.

### Cardio3 BioSciences – Financial Calendar 2015

- Thursday 26 March 2015: 2014 Financial and Operational results
- Tuesday 5 May 2015: Annual Shareholders Meeting
- Tuesday 19 May 2015: Q1 2015 Business Update
- Tuesday 25 August 2015: 2015 Half Year Financial and Operational results
- Thursday 19 November 2015: Q3 2015 Business Update

Calendar also available on: [www.c3bs.com/en/financial-calendar](http://www.c3bs.com/en/financial-calendar)

\*\*\* END \*\*\*

For more information, please contact:

#### **Cardio3 BioSciences**

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

[www.c3bs.com](http://www.c3bs.com)

Tel: +32 10 39 41 00

[jgrade@c3bs.com](mailto:jgrade@c3bs.com)

#### **For Europe: Consilium Strategic Communications**

Amber Bielecka, Chris Welsh, Laura Thornton

Tel : +44 20 3709 5700

[cardio3@consilium-comms.com](mailto:cardio3@consilium-comms.com)

#### **For the U.S: The Ruth Group**

Lee Roth (Investors), Kirsten Thomas (Media)

Tel: +1 646 536 7012 / 7014

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

To subscribe to Cardio3 BioSciences' newsletter, visit [www.c3bs.com](http://www.c3bs.com).

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

### **About Cardio3 BioSciences**

Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Company's lead product candidate in cardiology is C-Cure<sup>®</sup>, an autologous stem cell therapeutic using guided stem cells for the condition of congestive heart failure. The Company's lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including hematologic cancers and solid tumors. Cardio3 BioSciences is also developing a



PRESS RELEASE

23 JANUARY 2015 – 5 :45 PM CET

portfolio of medical devices for enhancing the delivery of bio therapeutic agents into the myocardium (C-Cath<sub>ez</sub><sup>®</sup>) and for cardiac surgery involving mitral valve defects.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

To learn more about Cardio3 BioSciences, please visit [www.c3bs.com](http://www.c3bs.com)

*C3BS-CQR-1, C-Cure, CM-CS1, C-Cath<sub>ez</sub>, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath<sub>ez</sub>, CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.*